|
CCDC50 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.25337542964144E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.70410005287891E-09 |
| Normal-vs-Stage2 |
5.41519995511663E-09 |
| Normal-vs-Stage3 |
2.96862534554521E-12 |
| Normal-vs-Stage4 |
1.07429953821736E-10 |
| Stage1-vs-Stage2 |
1.341430E-01 |
| Stage1-vs-Stage3 |
4.601200E-03 |
| Stage1-vs-Stage4 |
1.727860E-02 |
| Stage2-vs-Stage3 |
5.567400E-01 |
| Stage2-vs-Stage4 |
4.692600E-01 |
| Stage3-vs-Stage4 |
8.480800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.10973469197506E-12 |
| Normal-vs-AfricanAmerican |
4.14879999999229E-06 |
| Normal-vs-Asian |
2.05659999999996E-05 |
| Caucasian-vs-AfricanAmerican |
9.725800E-01 |
| Caucasian-vs-Asian |
2.268600E-01 |
| AfricanAmerican-vs-Asian |
4.114400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.0926999567148E-09 |
| Normal-vs-Female |
5.02353714182391E-12 |
| Male-vs-Female |
5.010000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.32700000046826E-07 |
| Normal-vs-Age(41-60Yrs) |
3.26172422404625E-12 |
| Normal-vs-Age(61-80Yrs) |
4.13746814587057E-12 |
| Normal-vs-Age(81-100Yrs) |
2.620300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.921500E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.742600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.610400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.756800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.982600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.909000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.167330E-04 |
| Classical-VS-Follicular |
2.792000E-01 |
| Classical-VS-Other |
3.797000E-01 |
| Classical-VS-Normal |
7.29910021313174E-10 |
| Tall-VS-Follicular |
3.922600E-03 |
| Tall-VS-Other |
2.443600E-01 |
| Tall-VS-Normal |
9.62940838178383E-12 |
| Follicular-VS-Other |
6.995800E-01 |
| Follicular-VS-Normal |
7.76809999658568E-08 |
| Other-VS-Normal |
2.079600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.7388979145494E-11 |
| Normal-vs-N1 |
2.99600000364109E-08 |
| N0-vs-N1 |
9.359000E-01 |
|
|
